Generic Name and Formulations:
Insulin aspart 100 Units/mL; soln for SC or IV inj; contains m-cresol, zinc.
Indications for FIASP:
Individualize. SC inj: give at start of meal or within 20mins after starting meal. Rotate inj sites (abdomen, upper arm, thigh). Use with intermediate or long-acting insulin. IV infusion: give under medical supervision with close monitoring (see full labeling). Switching from other insulins: convert on a unit-to-unit basis (see full labeling). Onset approx. 15–20mins, peak approx. 1.5–2hrs, duration approx. 5–7hrs.
During episodes of hypoglycemia.
Do not share pens between patients, or needles and syringes when using vials. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hypo- or hyperglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, somatostatin analogs (eg, octreotide), sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, phenothiazines, sympathomimetics, somatropin, thyroid hormones, oral contraceptives, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia.
Hypoglycemia, allergic reactions, hypersensitivity, inj site reactions, lipodystrophy, weight gain, hypokalemia, peripheral edema.
Vials (10mL)—1; FlexTouch (3mL prefilled pen)—1
Neurology Advisor Articles
- Deep Brain Stimulation Improves Parkinson Disease in Older Adults
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis